Pharma BD Deal Intelligence
A cheap options play: Merck paid just $175M upfront for seven preclinical Kelun-Biotech ADC candidates against up to $9.3B in milestones, betting on unproven pipeline depth rather than any de-risked asset.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Merck has agreed to pay up to $9.5 billion to license seven preclinical antibody-drug conjugate candidates from China's Kelun-Biotech, the latest in a series…
Merck has signed its third licensing deal with Chinese biotech Kelun-Biotech in less than a year, this time for seven preclinical ADC candidates worth up to…
Merck exercised an option to acquire global rights to SKB571, a bispecific ADC targeting solid tumors in lung and gastrointestinal cancers, for $37.5 million,…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Merck and Kelun-Biotech entered an exclusive license and collaboration agreement for seven investigational preclinical ADC candidates for cancer. Kelun-Biotech received $175M upfront plus an undisclosed equity investment, with up to $9.3B in development, regulatory and sales milestones plus tiered royalties. Kelun-Biotech retains rights for mainland China, Hong Kong and Macau.
500K US cases/yr · $28.0B Global ADC oncology market 2023 · ~$9.5B Total deal BD value (up to, incl. milestones)
The seven-ADC Merck/Kelun deal targets a broad solid-tumor opportunity anchored by TROP2 (SKB264/MK-2870), CLDN18.2 (SKB315), HER3, and other validated tumor-associated antigens. TROP2-directed ADCs address lung adenocarcinoma (~236,000 U.S. annual NSCLC cases, ~85% non-squamous), hormone receptor-positive breast cancer (~280,000 U.S. breast cases, ~70% HR+), and triple-negative breast cancer (~40,000 U.S. cases annually). CLDN18.2 ADCs address gastric/GEJ cancer (~27,000 U.S. cases) and pancreatic adenocarcinoma (~64,000 U.S. cases), segments where CLDN18.2 is expressed in 30-50% of tumors. The global market opportunity is substantial — Merck has publicly articulated a multi-decade oncology franchise strategy post-Keytruda LOE (2028-2029), and ADCs are the single largest bet in that franchise rebuild. Pricing for ADCs in solid tumors ranges from $14K-22K per month WAC in the U.S., and the 7-asset portfolio offers Merck optionality across I/O combinations, HER2/HER3 refractory settings, and GI tumors where checkpoint inhibition alone has underperformed.
The ADC landscape Merck is buying into is the most crowded oncology modality outside checkpoint inhibitors. Validated ADC assets include Enhertu (trastuzumab deruxtecan, Daiichi/AZ) dominating HER2-low/positive breast; Trodelvy (sacituzumab govitecan, Gilead) in TNBC and HR+/HER2- breast; Padcev (enfortumab vedotin, Pfizer/Astellas) anchoring urothelial; Elahere (mirvetuximab soravtansine, AbbVie/ImmunoGen) in FRα+ platinum-resistant ovarian; and Blenrep (belantamab mafodotin, GSK) re-emerging in R/R multiple myeloma. Kelun's SKB264 (TROP2 ADC, now MK-2870) competes head-on with Trodelvy and Datopotamab deruxtecan (Dato-DXd, Daiichi/AZ). SKB315 (CLDN18.2 ADC) is one of roughly 12 CLDN18.2 ADCs in clinical development globally. Merck's platform play positions it against AstraZeneca/Daiichi's seven-asset ADC alliance, creating a two-player ADC scale race that dwarfs other consolidators.
Days after the ~$4B Daiichi Sankyo ADC deal (Oct 2023), Merck terminated the license on one preclinical Kelun ADC and declined an option on a second due to target overlap with the Daiichi clinical-stage assets.
Merck exercised its option on SKB571 (EGFR x cMet bispecific ADC for lung/GI solid tumors) for $37.5M plus milestones and tiered royalties, while concurrently returning global rights to the CLDN18.2-directed ADC SKB315 to Kelun-Biotech.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (this deal) | 2023 | $9.5B | — |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2023 deals · Merck & Co. Inc. deals · Oncology deals